Impact of Tenofovir gel as a PrEP on HIV infection: A mathematical model

被引:4
|
作者
Rahman, S. M. Ashrafur [1 ]
Vaidya, Naveen K. [2 ]
Zou, Xingfu [1 ]
机构
[1] Univ Western Ontario, Dept Appl Math, London, ON N6A 5B7, Canada
[2] Univ Missouri, Dept Math & Stat, Kansas City, MO 64110 USA
基金
加拿大自然科学与工程研究理事会;
关键词
HIV; PrEP; Tenofovir gel; Transmission rate; Mathematical model; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; PREVENTION; ZIDOVUDINE; TRIAL; METAANALYSIS; HIV/AIDS; THAILAND; COUPLES; FEMALE;
D O I
10.1016/j.jtbi.2013.12.021
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pre-exposure prophylaxis (PrEP) has been considered as one of the promising interventions for HIV infection as experiments on various groups and sites have reported its significant effectiveness. This study evaluates the effectiveness of Tenofovir gel, one of the widely used PrEPs for women, through a mathematical model. Our model has excellent agreement with the experimental data on the use of Tenofovir gel as a PrEP in South African women. Using our model, we estimate both male-to-female and female-to-male transmission rates with and without Tenofovir gel protection. Through these estimates we demonstrate that the use of Tenofovir gel as a PrEP can significantly reduce the reproduction numbers, new infections, and HIV prevalence in South Africa. Our results further show that the effectiveness of Tenofovir gel largely depends on the level of adherence to the gel and the proportion of women under gel coverage. Even though Tenofovir gel alone may not be able to eradicate the disease as indicated by our estimates of the reproduction numbers, together with other interventions, such as condom use, it can serve as a strong weapon to fight against HIV epidemics. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 50 条
  • [21] Analysis of HIV Infection in Cyprus Using a Mathematical Model
    Sultanoglu, Nazife
    Saad, Farouk
    Sanlidag, Tamer
    Hincal, Evren
    Sayan, Murat
    Kaymakamzade, Bilgen
    Suer, Kaya
    ERCIYES MEDICAL JOURNAL, 2022, 44 (01) : 63 - 67
  • [22] HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention
    Donnell, Deborah
    Baeten, Jared M.
    Bumpus, Namandje N.
    Brantley, Justin
    Bangsberg, David R.
    Haberer, Jessica E.
    Mujugira, Andrew
    Mugo, Nelly
    Ndase, Patrick
    Hendrix, Craig
    Celum, Connie
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (03) : 340 - 348
  • [23] HIV seroconversions in the PrEP impact trial
    Cartier, A.
    Milinkovic, A.
    Pereira, B.
    Reeves, I.
    Ogaz, D.
    Mitchell, H.
    Saunders, J.
    Charlett, A.
    Chiavenna, C.
    Sullivan, A.
    HIV MEDICINE, 2023, 24 : 498 - 499
  • [24] A retrospective analysis of bone loss in tenofovir-emtricitabine therapy for HIV PrEP
    Chang, Joseph
    Duy Do
    Delgado, Hector
    Kanimian, Natalie
    An Huynh
    INTERNATIONAL JOURNAL OF STD & AIDS, 2022, 33 (14) : 1183 - 1192
  • [25] Ethics and HIV prevention research: An analysis of the early tenofovir PrEP trial in Nigeria
    Peterson, Kristin
    Folayan, Morenike O.
    BIOETHICS, 2019, 33 (01) : 35 - 42
  • [26] Characterization of UC781-Tenofovir Combination Gel Products for HIV-1 Infection Prevention in an Ex Vivo Ectocervical Model
    Cost, Marilyn
    Dezzutti, Charlene S.
    Clark, Meredith R.
    Friend, David R.
    Akil, Ayman
    Rohan, Lisa Cencia
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) : 3058 - 3066
  • [27] Tenofovir alafenamide for HIV infection: is less more?
    Wyatt, Christina
    Baeten, Jared M.
    LANCET, 2015, 385 (9987): : 2559 - 2560
  • [28] TENOFOVIR ALAFENAMIDE FUMARATE FOR THE TREATMENT OF HIV INFECTION
    Sampath, R.
    Zeuli, J.
    Rizza, S.
    Temesgen, Z.
    DRUGS OF TODAY, 2016, 52 (11) : 617 - 625
  • [29] Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection
    Ham, Anthony S.
    Ugaonkar, Shweta R.
    Shi, Lianjun
    Buckheit, Karen Watson
    Lakougna, Howard
    Nagaraja, Umadevi
    Gwozdz, Garry
    Goldman, Laurie
    Kiser, Patrick F.
    Buckheit, Robert W., Jr.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (04) : 1423 - 1435
  • [30] Tenofovir disoproxil fumarate for the treatment of HIV infection
    Pham, Paul A.
    Gallant, Joel E.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (03) : 459 - 469